Search Results - "Scaramucci, J O"

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) by Rudick, R A, Simonian, N A, Alam, J A, Campion, M, Scaramucci, J O, Jones, W, Coats, M E, Goodkin, D E, Weinstock-Guttman, B, Herndon, R M, Mass, M K, Richert, J R, Salazar, A M, Munschauer, 3rd, F E, Cookfair, D L, Simon, J H, Jacobs, L D

“…Interferon beta is an effective treatment for relapsing multiple sclerosis (MS). As with other protein drugs, neutralizing antibodies (NAB) can develop that…”
Get full text

Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis by Herndon, RM, Jacobs, LD, Coats, ME, Goodkin, DE, Mass, MK, Richert, JR, Rudick, RA, Waubant, EL, Weinstock-Guttman, B, Scaramucci, JO, Burnett, BK, Jones, WE, Simonian, NA

“…Abstract In a phase III, double-blind, placebo-controlled, 2-year clinical trial, interferon beta-1a (IFN-β-1a, Avonex) treatment significantly delayed…”
Get full text